AB
PVLA

Amalgamated Bank’s Palvella Therapeutics PVLA Stock Holding History

Amalgamated Bank’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-227
Closed -$24K – 2909
2025
Q4 		$24K Sell
227
-7
-3% -$597 ﹤0.01% 2041
2025
Q3 		$15K Hold
234
– – ﹤0.01% 2284
2025
Q2 		$5K Buy
+234
New +$5.49K ﹤0.01% 2803

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Amalgamated Bank's PVLA Position: Q1 2026 in Review

Amalgamated Bank sold out of Palvella Therapeutics (PVLA) in Q1 2026, closing a stake of 227 shares — an estimated $24K sold.

Amalgamated Bank first reported a position in PVLA in Q2 2025 and held it in 3 quarters. The position peaked at $24K in Q4 2025. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Amalgamated Bank reported no remaining Palvella Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 227 Palvella Therapeutics shares in Q1 2026, an estimated $24K.
  • Amalgamated Bank first reported a position in Palvella Therapeutics in Q2 2025 and held it in 3 quarters.
  • Amalgamated Bank's Palvella Therapeutics position peaked at $24K in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.